Oppenheimer maintains an 'Outperform' on Emerson (EMR); Transition Tempers Timing, But Backlog Offers Tailwind

March 15, 2012 12:55 PM EDT
Get Alerts EMR Hot Sheet
Price: $163.17 -0.29%

Rating Summary:
    26 Buy, 20 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Oppenheimer maintains an 'Outperform' on Emerson (NYSE: EMR) price target raised from $58 to $61.

Oppenheimer analyst said, "We estimate investor sentiment as anticipating that EMR likely capitulates on present guidance for FY12 EPS of $3.45-3.60 (up 7-11% y-o-y), given that 1Q EPS of $0.50 declined 21% y-o-y. We do not: we believe EMR is well positioned to hold the bottom 2/3 of the range intact, which would straddle our at-consensus FY12E of $3.50. Cost accounting vs. timing of revenue recognition at Process Management due to Thailand impact (shipment deferrals) should drive unprecedented FY2H OM at PM. With PM by far the largest component of the FY1Q12 y-o-y profit decline, the FY2H benefits from timing and margin impacts of shipments relative to production may not be fully appreciated."

For an analyst ratings summary and ratings history on Emerson click here. For more ratings news on Emerson click here.

Shares of Emerson closed at $51.72 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change